A woman with systemic lupus erythematosus (SLE) with marked increases in circulating 150-kDa PRL was studied from before conception, throughout pregnancy, and after pregnancy. The clinical features of the patient included idiopathic hyperprolactinemia without clinical symptoms such as amenorrhea and galactorrhea before pregnancy. No clinical lupus activity was present during follow-up. Serum PRL increase during pregnancy in this patient was considerably higher at weeks 27 and 33 than in normal pregnant women. In contrast, serum-free PRL levels were considerably lower at weeks 20, 27, and 33 than in normal pregnant women. A 150-kDa PRL (big big PRL) species persisted as the predominant circulating form of PRL throughout each measurement in this woman with SLE. In contrast, the predominant form of PRL in serum from healthy pregnant women was little PRL (or monomeric PRL). The nature of big big PRL was due to the presence of anti-PRL autoantibodies forming an IgG-23 kDa PRL complex, in accordance with the studies by affinity chromatography for IgG and Western blot analysis. The IgG-PRL complex was fully bioactive in vitro (Nb2 rat lymphoma cell assay). Injection of the serum into the rats demonstrated that the IgG-PRL complex was cleared more slowly than serum containing predominantly monomeric PRL. The data suggest that the IgG-PRL complex has biological activity; the absence of symptoms in this woman may be attributed to the fact that due to its large molecular weight, big big PRL does not easily cross the capillary walls. Delayed clearance may account for increased serum PRL levels in this SLE patient with anti-PRL autoantibodies. (J Clin Endocrinol
I
N SERUM FROM normal subjects and most patients with hyperprolactinemia, the majority of PRL immunoreactivity is found by gel filtration column chromatography to have an apparent molecular weight of ϳ23K (little PRL). Lesser amounts are found in the void volume (big big PRL Ͼ100 kDa) or in a position corresponding to a molecular weight of 45-50K (big PRL). Several authors have reported a small number of patients with asymptomatic hyperprolactinemia, such as the absence of amenorrhea and/or galactorrhea, because of the predominant presence of big big PRL, a phenomenon termed macroprolactinemia (1) (2) (3) . Macroprolactinemia has been reported mainly as the cause of idiopathic hyperprolactinemia (4 -6) . Although the nature of macroprolactin is still unclear, this isoform of PRL seems to be a postsecretory event (aggregates of monomeric PRL and PRL-bound to binding proteins). These modifications of PRL may affect their biological properties differently from immunoreactivity (7) . Recent evidence indicates that big big PRL is mostly an IgG-23 kDa PRL complex (anti-PRL autoantibody); this anti-PRL autoantibody has been reported in sera from 16% of patients with idiopathic hyperprolactinemia (without autoimmune disorders) (8) . In contrast, we have recently shown in systemic lupus erythematosus (SLE) patients without proven cause of hyperprolactinemia that the frequency of macroprolactinemia due to anti-PRL autoantibodies was higher (40.7%) (9) . Interestingly, patients with anti-PRL autoantibodies had less clinical and serological SLE activity than those without anti-PRL autoantibodies (with only the presence of monomeric or little PRL in their blood). PRL has effects on B and T cells. Moreover, high serum PRL levels have been associated to lupus activity (10, 11) . A possible explanation for the lesser lupus activity in the SLE patients with anti-PRL autoantibodies is that PRL has attenuated biological activity when bound to its autoantibody, interfering with PRL receptor binding on lymphocytes and/or because it does not easily cross the capillary walls to reach lymphoid tissues due to its high molecular weight.
On the other hand, both macroprolactinemia related or not to anti-PRL autoantibodies have the following similarities: 1) large molecular weight (Ͼ100K) and 2) lack of clinical symptoms of hyperprolactinemia. In the few cases reported, women with macroprolactinemia usually retain fertility (10 -13) . We recently had the opportunity to prospectively follow a SLE woman with known macroprolactinemia due to the presence of anti-PRL autoantibody during pregnancy. This report describes the circulating forms of PRL and the binding of serum PRL to G protein in this woman with SLE (before, during, and after pregnancy). In addition, biological activity of PRL in fractions obtained after gel filtration and the characterization of PRL after SDS-PAGE and Western blot analysis were examined. Finally, an endocrinological evaluation and a clearance study of PRL into rats were performed.
Patients and Methods
The Human Ethical Committee and Medical Research of the Institute approved the study protocol, and informed written consent was obtained from all subjects who participated voluntarily in this study. The animals were cared for according to the Guide for the Care and Use of Laboratory Animals.
Case report
A 21-yr-old woman, who 7 yr earlier was diagnosed as having SLE, manifested by fatigue, arthralgias, arthritis, pleuresy, leukopenia, lymphopenia, positive antidouble-stranded DNA (ds-DNA) antibodies, and a positive fluorescent antinuclear antibody test (1:2560), was studied. Her menarche occurred at age 14, and she had been pregnant at the age of 18 yr. Her menstrual cycle had always been regular. In October 1996 (at age 19), her PRL level was measured because she was included in another study that we recently published (9) . From October 1996 to August 1997, PRL levels ranged from 70.4 -90.5 g/L (normal, 0 -20 g/L); the patient had no evidence of pituitary adenoma on computed tomography, nor did she have known causes for secondary hyperprolactinemia. She again spontaneously became pregnant in December 1997, and at 36 weeks of pregnancy she underwent cesarean surgery due to the premature rupture of membranes. The woman did not breast-feed her baby for medical reasons; however, she exhibited galactorrhea for 5 days postcesarean, and menses became regular at 45 days postcesarean. Over the next 10 months, serum PRL levels fluctuated between 66.9 and 115.5 g/L. Blood samples were drawn at 20, 27, and 33 weeks of pregnancy. As a control, 40 pregnant but otherwise healthy women (9 at week 20, 10 at week 27, and 21 at week 33) were also studied. Hyperprolactinemia was evaluated at 10 months postcesarean by the administration of metoclopramide (10 mg, iv) and bromocriptine (BRC; 2.5 mg/day for 2 weeks). During follow-up, she did not manifest clinical SLE activity and was treated during this time with prednisone (5-20 mg/day). However, she continued to exhibit the presence of antibodies to ds-DNA, Ro/SSA, La/SSB, Smith antigen, ribonucleoprotein, and antinuclear (Table 1) .
Hormonal assays
PRL concentrations in serum and fractions by chromatographic studies were measured by immunoradiometric assay (IRMA) (ELSA-PRL; CIS-Bio International, Gif-sur-Yvette, France). The limit of sensitivity of the assay was 0.09 g/L. Anti-PRL autoantibody was found not to interfere with present IRMA for PRL (14) . Normal levels of PRL are 5-20 g/L. Free PRL was extracted from the sera according to the method described previously (9) . Intra-assay and interassay coefficients of variation were 8% or less in all tests.
Chromatography
Gel filtration was performed using a column (60 ϫ 1.5 cm) of Sephadex G-200 Superfine (Pharmacia, Uppsala, Sweden), as described previously (9) . Serum samples of 2 mL were applied on the column, and fractions of 1.3 mL were collected for PRL assay in the same day. Recovery was 104.4 Ϯ 14.3%, on average. Affinity chromatographic for IgG was performed using a 1-mL G protein column (HiTrap G; Pharmacia LKB, Uppsala Sweden) as previously described (9) . IRMA assayed both retained and unretained fractions for PRL. When PRL standards were applied on the column, no PRL was bound to G protein (mean Ϯ sd, 1.9 Ϯ 3.5%).
PRL-dependent Nb2 lymphoma cell
PRL bioactivity in fractions on gel filtration before pregnancy was measured using Nb2 lymphoma cell assay as described by Tanaka et al. (15) , and similar to that described by Larrea et al. (16) . Recombinant human PRL (rhPRL) (Genzyme, Cambridge, MA) was used as standard PRL. To inhibit the lactogenic effect of human GH (hGH), rabbit antiserum to hGH [NIDDK-anti-hGH-IC-3 A.S., CYTO (AFPC11981A)] was added to a final dilution of 1:4000. The effects of rhPRL and PRL fractions by gel filtration on cell proliferation were analyzed by incorporation of [ 3 H]thymidine (1Ci) into Nb2 cells. When anti-hPRL was added to the Nb2 cell assay in the presence of antibodies to hGH, stimulation of the proliferation of Nb2 cell by serum fractions was completely abolished. Sensitivity of this assay for PRL was 3 pg/mL. Nb2 cell assay was carried out when the patient was not pregnant, because at the time of the study we did not have antiplacental lactogen antiserum.
Western blotting and immunostaining
The procedure used was similar to that reported by Sinha et al. (17) . Briefly, PRL samples were immunoprecipitated with rabbit anti-hPRL antiserum [NIDDK-anti-hPRL-IC-5, CYTO (AFP55781789SI)] for 72 h at 4 C and subsequently with goat antirabbit ␥-globulin antiserum (DAKO Corp., Carpinteria, CA) for 24 h at 4 C with continuous shaking. Normal rabbit serum without human samples was used as control. The precipitates were resuspended and dissolved in Laemmli's sample buffer and heated at 95 C for 5 min. Samples were electrophoresed on a 12% polyacrilamide gel in the presence of 0.1% SDS under reducing conditions (18) . After electrophoresis, proteins were electroblotted onto nitrocellulose paper in PAGE buffer containing 20% methanol without SDS (19) . Paper was fixed, blocked, and incubated for 4 h at room temperature in a 1:1000 final dilution of same rabbit anti-hPRL serum and afterward with a 1:2000 dilution of peroxidase-conjugated goat antirabbit serum (DAKO Corp.). Color developing solution was added to localize the immunocomplexes.
Clearance studies
One milliliter of serum from the woman with SLE or from a healthy pregnant woman (matched by serum PRL level) was rapidly injected via a femoral cannula into ketamine-anesthetized male Sprague Dawley rats (body weight, 300 g). Blood samples of 0.3 mL were withdrawn at 0, 1, 5, 10, 20, 40, 60, and 90 min. The rat plasmas were separated and frozen at Ϫ35 C until assayed for hPRL. Rat PRL was shown not to interfere with the present IRMA for hPRL.
Stimulation and suppression test for PRL
At 10 months postcesarean, a 10-mg dose of metoclopramide was injected as an iv bolus and blood was collected at 0, 30, 60, 90, and 180 min. Then, BRC was instituted at a dose of 2.5 mg/day for 2 weeks and blood was drawn at days 7 and 14.
Results
During follow-up of the patient before pregnancy, she had sustained hyperprolactinemia (70.4 -90.5 g/L), and gel filtration showed that the majority (75.4 -87.8%) of PRL immunoreactivity eluted at position 150 kDa (big big PRL), with 6.6 -16.6% eluting at the same position of 125 I-hPRL (little PRL, 23 kDa). These proportions of big big PRL did not change significantly after pregnancy 69.2-70.7% (Table 1 ). In the woman with SLE (Table 1 ), the serum total PRL level at 20 weeks gestation was 214.5 g/L, similar to mean than that of healthy pregnant women at the same gestation time [190.4 g/L; 95% confident interval (CI), 125.1-255.7 g/L]. At 27 and 33 weeks, serum total PRL levels in the woman with SLE were 483.7 and 427.1 g/L, respectively; in contrast, these concentrations were considerably lower in healthy pregnant women at 27 weeks (254.8 g/L; CI 95%, 201.5-308.0 g/L) and at 33 weeks (296.1 g/L; CI 95%, 267.9 -324.2 g/L). On the other hand, free PRL levels in the woman with SLE were considerably lower at weeks 20, 27, and 33 than that in healthy pregnant women (Table 1 ). Figure 1A shows the gel filtration profiles of PRL before, during, and after pregnancy in the SLE patient. As can be seen, during pregnancy almost all (66.6 -74.3%) PRL immunoreactivity eluted as big big PRL (150 kDa). In contrast, in the healthy pregnant women the 23-kDa PRL remained as the predominant species (Ն85.4% of total PRL at the same number of weeks gestation). As pregnancy progressed, all species of PRL increased, but the relative proportion remained the same. However, serum-free PRL levels increased 7.4-to 10.4-fold during pregnancy in comparison with the mean before pregnancy (8.8 g/L). In contrast, total PRL level increases were lower (5.2-to 5.9-fold) than the mean before pregnancy (81.7 g/L). Figure 1B shows affinity chromatography with G protein column profiles of serum PRL before, during, and after pregnancy in the SLE patient. As pregnancy progressed, there was a decrease in serum PRL retained by G protein column at 20 weeks (45.6%), 27 weeks (35.7%), and 33 weeks (29.5%), and serum PRL retained by the column at 4 weeks postpregnancy returned to prepregnancy values (Table 1 ). In contrast, in healthy pregnant women the proportion of PRL bound to G protein was considerably lower (Յ3.6%). The mean Nb2/IRMA ratio in all fractions was 1.54 (range, 1.19 -1.72), closely similar to mean ratio observed in the five peaks of the fractions containing big big PRL (1.54; range, 1.33-1.72) and in the five peaks of the fractions containing little PRL (1.57; range, 1.46 -1.68).
When whole serum or fractions containing big big PRL were analyzed on SDS-PAGE displayed one band on Western blot analysis, this band was a 23-kDa protein. When whole serum from a patient with pituitary adenoma was used, it displayed three bands (25, 23 and ϳ22 kDa). The pituitary hPRL [NIDKK-hPRL-SIAFP-B-3 (AFP-3855A), which was not immunoprecipitated] also elicited 25-and 23-kDa bands as well as others (60, 48, 20, 16.5, and 16 kDa). Finally, the same bands were also present in rhPRL (that was not immunoprecipitated), except the 25-kDa band (glycosylated PRL) (Fig. 2) .
Clearance studies using injections of whole human serum into rats demonstrated a slower removal of the PRL immunoreactivity in the SLE patient compared with healthy pregnant woman (Fig. 3) . More than 50% of immunoreactive PRL was present until 90 min when the serum from the woman with SLE was injected. In contrast, more than 50% of immunoreactive PRL was cleared from circulation at 5 min when the serum from healthy pregnant woman was injected.
After iv injection of metoclopramide (antidopaminergic drug) in the woman with SLE, the serum PRL level rose from a baseline concentration of 66.9 to a peak of 239.2 g/L at 30 min and slowly declined to 207.4, 189.2, and 83.4 g/L at 60, 90, and 180 min, respectively. A similar response was observed in free PRL levels (Table 1) . Gel filtration revealed that the increase in PRL levels by metoclopramide at 30 min consisted almost entirely of 23-kDa PRL (60.4 vs. 25.2% in the basal state). Also, PRL bound to G protein decreased from a baseline proportion of 33.3% to 21.4% at 30 min and slowly increased to the basal value (Table 1) . Serum PRL levels were suppressed by BRC to 17.0 g/L at 7 days and to 15.6 g/L at 14 days. On the other hand, gel filtration showed that when the PRL standard was mixed with serum (1 mL) from a normal woman, 
FIG. 1.
A, The change in gel filtration profiles of immunoreactive PRL in serum before, during, and after pregnancy from a hyperprolactinemic SLE woman on a Sephadex G-200 column (60 ϫ 1.5 cm). Samples (2 mL) were applied in the column, and fractions of 1.3 mL were collected (F, before pregnancy; OE, pregnancy at week 20; ࡗ, pregnancy at week 27; ‫,ء‬ pregnancy at week 33; f, after pregnancy). B, Affinity chromatography profiles of immunoreactive PRL on a G protein Sepharose column (1 mL). Samples (1 mL) were applied in the column, and fractions of 1.5 mL were collected (F, before pregnancy; OE, pregnancy at week 20; ࡗ, pregnancy at week 27; ‫,ء‬ pregnancy at week 33; f, after pregnancy).
the majority of PRL immunoreactivity eluted as 23 kDa PRL (92.9%), with 4.3% eluting as big big PRL. In contrast, these proportions changed significantly after mixing PRL standard with serum from the woman with SLE (at 14 days with BRC); 23.8% of PRL immunoreactivity eluted at position 150 kDa (big big PRL) and with 67.8% as 23 kDa PRL. Also, the proportion of PRL bound to G protein was significantly higher in PRL standard mixed with serum from the woman with SLE (20.2 vs. 1.0% in serum from healthy woman) (Table 1) .
Discussion
Hyperprolactinemic patients usually have galactorrhea, menstrual irregularity, and infertility (20 -22) . Conception usually occurs only after treatment with dopaminergic agonist (23) (24) (25) (26) . In contrast, there is a subgroup of women with a large molecular size form of PRL who retain fertility despite sustained hyperprolactinemia (12, 13, 27) . We found that the woman with SLE spontaneously became pregnant; the course of pregnancy was uneventful, and her infant was normal. These results are similar to those described in hyperprolactinemic women with macroprolactinemia related or not to anti-PRL autoantibody (12, 28) .
The proportion of little PRL has been reported to be increased during pregnancy in normal women and patients with macroprolactinemia (28, 29) . In the case under study, we found that as pregnancy progressed big big, big, and little PRL all increased, but the relative proportion of little PRL increased dramatically. Release of little PRL from the pituitary gland may increase as pregnancy progresses, and a part of little PRL binds to anti-PRL autoantibody, leading to an increase in big big PRL. However, an increase in little PRL may exceed the binding capacity of the autoantibody, leading to an additional increase in little PRL. PRL levels may become extremely high during pregnancy because big big PRL may not exert a physiological feedback action on the pituitary gland, as little PRL and serum PRL levels may increase until little PRL reaches its physiological level.
In normal women, serum PRL values during pregnancy increase 10-to 20-fold (29, 30) . In contrast to normal women, the PRL increment in our hyperprolactinemic woman was considerably less. Lesser serum PRL increases during pregnancy also have been reported in women with other forms of hyperprolactinemia (31, 32) . In fact, there is no uniform pattern of PRL increases during gestation in hyperprolactinemic women; the changes range from normal increments in PRL levels during pregnancy to decreases at the time of delivery (33) . However, free PRL levels during pregnancy in the patient under study were lower than those in normal pregnant women but increased as much as 10-fold compared with before pregnancy. These results are similar to those described in normal pregnant women whose predominant circulating species was little PRL (29, 30) .
Although several investigators have reported patients with macroprolactinemia, the nature of big big PRL is still controversial (12, 28, 34) . In this case, it was due to the presence of a PRL-anti-PRL autoantibody complex. The diagnosis of the presence of an anti-PRL autoantibody was based on the following: 1) PRL immunoreactivity was predominantly eluted at the position of 150K molecular weight, similar to that of IgG; and 2) significantly large amounts of PRL were adsorbed by the affinity column for IgG.
A significant but lower proportion of serum PRL was retained by G protein Sepharose column than by filtration gel. This is probably because during affinity chromatography with G protein Sepharose there is a dissociation of PRL from its autoantibody, underestimating the proportion of big big PRL retained by the G protein Sepharose column. This dissociation can be explained by a low affinity of the autoantibody to PRL. However, there is an amount of big big PRL that is not IgG bound and that most likely represents PRL bound to other proteins that are not retained by G protein or other immunoglobulin isotypes binding to PRL, as reported for other autoantigens in sera SLE (IgA and IgM).
The clinical features of the present patient with macroprolactinemia include idiopathic hyperprolactinemia, without clinical symptoms such as amenorrhea and galactorrhea before pregnancy and very high levels of PRL during pregnancy. In addition, other studies have reported the presence of high PRL levels during pregnancy in women with anti-PRL autoantibody (without autoimmune disease) compared with pregnant women without macroprolactinemia (28, 35) . The lack of clinical symptoms of hyperprolactinemia cannot be attributed to low biological activity of big big PRL; biological activity (Nb2 cell assay) in fractions containing big big PRL yielded the same results as in fractions containing little PRL. However, in vivo big big PRL may not exert enough action because it does not easily cross the capillary walls due to its high molecular weight. On the other hand, clearance studies in rats showed that the IgG-PRL complex is eliminated more slowly from the bloodstream than serum containing only monomeric PRL, these data according to those found by Hattori and Inagaki (36) , who postulated that this could be another mechanism in which PRL is retained in circulation for a long time (prolonged half-life).
It is of interest that an antidopaminergic agent elicited a normal response of PRL secretion. Indeed, total PRL levels exceeded the binding capacity of anti-PRL auto- antibodies, resulting in an increase in free PRL level (monomeric PRL), a finding similar to that displayed during pregnancy in this woman with SLE. BRC had a suppressive effect on PRL levels, which returned to normal values (Ͻ20 g/L). One hundred fifty kilodaltons of PRL can be made in vitro by mixing PRL standard (23 kDa) with serum (obtained at 14 days post-BRC) from the woman with SLE, suggesting that 150 kDa PRL is the result of the binding of 23 kDa PRL to anti-PRL autoantibody, as confirmed by affinity chromatography on G protein and Western blot analysis.
In mice and humans, SLE flares increase during pregnancy; this has been associated with raising serum PRL levels (37) (38) (39) (40) . We have previously shown that hyperprolactinemic SLE patients with anti-PRL autoantibodies had less SLE activity compared with those without anti-PRL autoantibodies (9) , suggesting that the anti-PRL autoantibody may interact on the SLE disease spectrum. However, further research is needed to define the mechanism and importance of these findings. Nevertheless, in this woman with SLE during follow-up, the disease activity of the patient remained stable even of incurring in persistence of hyperprolactinemia.
